GH Research (NASDAQ:GHRS) Lowered to Strong Sell Rating by Zacks Research

Posted by Brian Himes on Jul 17th, 2026

Zacks Research cut shares of GH Research (NASDAQ:GHRS – Free Report) from a hold rating to a strong sell rating in a research note published on Wednesday,Zacks.com reports.

Several other research firms also recently weighed in on GHRS. Citigroup reissued an “outperform” rating on shares of GH Research in a report on Friday, May 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of GH Research in a report on Tuesday, April 21st. Citizens Jmp dropped their target price on GH Research from $42.00 to $39.00 and set a “market outperform” rating for the company in a research report on Friday, May 15th. Cantor Fitzgerald lifted their price target on GH Research from $25.00 to $35.00 and gave the company an “overweight” rating in a research note on Friday, May 15th. Finally, HC Wainwright reduced their price target on GH Research from $70.00 to $65.00 and set a “buy” rating on the stock in a report on Tuesday, May 19th. Nine equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $40.38.

Check Out Our Latest Analysis on GHRS

GH Research Price Performance

Shares of GH Research stock opened at $29.13 on Wednesday. GH Research has a fifty-two week low of $11.32 and a fifty-two week high of $31.00. The firm has a market capitalization of $2.00 billion, a P/E ratio of -31.66 and a beta of 1.28. The company’s 50 day moving average price is $23.66 and its two-hundred day moving average price is $18.67.

GH Research (NASDAQ:GHRS – Get Free Report) last posted its earnings results on Thursday, May 14th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.04). On average, analysts expect that GH Research will post -1.46 earnings per share for the current year.

Institutional Trading of GH Research

Several institutional investors have recently modified their holdings of GHRS. JPMorgan Chase & Co. bought a new stake in shares of GH Research in the 2nd quarter valued at about $79,000. BNP Paribas Financial Markets lifted its stake in shares of GH Research by 165.4% in the second quarter. BNP Paribas Financial Markets now owns 17,010 shares of the company’s stock worth $207,000 after acquiring an additional 10,600 shares during the period. Osaic Holdings Inc. boosted its holdings in GH Research by 63.6% in the second quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock valued at $75,000 after acquiring an additional 2,400 shares during the last quarter. UBS Group AG boosted its holdings in GH Research by 11.5% in the third quarter. UBS Group AG now owns 511,464 shares of the company’s stock valued at $7,314,000 after acquiring an additional 52,882 shares during the last quarter. Finally, Lynx1 Capital Management LP increased its position in GH Research by 27.5% during the 3rd quarter. Lynx1 Capital Management LP now owns 8,601,189 shares of the company’s stock valued at $122,997,000 after purchasing an additional 1,854,238 shares during the period. Institutional investors own 56.90% of the company’s stock.

About GH Research

(Get Free Report)

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.